Drug Profile
GSK 932121
Alternative Names: 932121; 932121A; GSK-932121; GSK-932121ALatest Information Update: 01 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; Medicines for Malaria Venture
- Developer GSK
- Class Fluorine compounds; Phenyl ethers; Pyridones; Small molecules
- Mechanism of Action Electron transport complex I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 02 Aug 2013 No development reported - Phase-I for Malaria in Australia (unspecified route)
- 15 Apr 2011 GlaxoSmithKline terminates phase I trial in Healthy volunteers in Australia (NCT00811356)
- 26 Mar 2010 Phase-I clinical trials in Malaria in Australia (unspecified route)